Skip to content

Arabic Version of the EARS Questionnaire

Cross-cultural Adaptation and Psychometric Properties of the Arabic Version of the Exercise Adherence Rating Scale

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04909099
Acronym
EARS-Ar
Enrollment
120
Registered
2021-06-01
Start date
2022-02-15
Completion date
2022-12-31
Last updated
2022-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis, Low Back Pain

Brief summary

A study to translate and cross-culturally adapt the Exercise Adherence Rating Scale (EARS) into the Arabic language, and assess its psychometric properties.

Interventions

OTHERStandard treatment

Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC). The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness.

Sponsors

King Fahd Military Medical Complex
CollaboratorUNKNOWN
Prince Sultan Military College of Health Sciences
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Low back pain patients: aged 18 years or older, experienced non-specific CLBP of 3 months or longer, pain localized to the lumbar region. * Knee OA patients: eligible participants must meet the knee OA diagnostic criteria according to the American College of Rheumatology (ACR).

Exclusion criteria

* degenerative systemic diseases * neurological symptoms * lumbar stenosis * spondylolisthesis * history of spinal or knee surgeries * pregnancy * rheumatoid arthritis * serious pathological conditions (inflammatory arthritis and malignancy) * individuals who cannot read and understand documents written in the Arabic language.

Design outcomes

Primary

MeasureTime frameDescription
Floor and ceiling effect1 dayIt will be considered present if more than 15% of the sample score the lowest or highest possible total score, respectively
Content Validity1 dayAssessed using the Content Validity Index (CVI) with an acceptable value of at least 0.8.
Construct Validity1 dayAssessed by calculating the Spearman's correlation coefficient (ρ) between the Exercise Adherence Rating Scale-Arabic version (EARS-Ar) score and the Fear Avoidance Belief Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), the Roland-Morris Disability Questionnaire (RMDQ), and the Knee Injury and osteoarthritis Outcome Score (KOOS) measurement tools. The coefficient is classified as follows: ρ = 0.3-0.7 moderate correlation, and \>0.7 strong correlation.
Internal Consistency3-7 daysAssessed by calculating the Cronbach's alpha (α) and the corrected item-total correlation. A Cronbach's α value of ≥0.7, and a corrected item-total correlation, measured using the Pearson correlation coefficient, of ≥0.3 will be considered acceptable.
Test-retest Reliability3-7 daysAssessed by calculating the intraclass correlation coefficient (ICC) between the EARS-Ar scores of the first two test sessions. An ICC value of \>0.8 and 0.6-0.8 will be considered as excellent and good correlation, respectively.

Secondary

MeasureTime frameDescription
Responsiveness3 weeksParticipating patients will be categorized according to their reported Global Rating of Change (GRoC) scores (external anchor) to either improved (GRoC≥3) or stable group (GRoC\<3 to \>-3) and a between-group comparison will be performed using an unpaired t-test.

Countries

Saudi Arabia

Contacts

Primary ContactAhmed Farrag, PhD
ahmedfarrag@cu.edu.eg+966 546767865

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026